Clinical Comprehensive Evaluation of Neuroprotective Drugs for Acute Ischemic Stroke
Ischemic strok
1 other identifier
observational
600
0 countries
N/A
Brief Summary
This study conducted a comprehensive evaluation of commonly used neuroprotective agents in acute ischemic stroke, assessing their real-world value across six dimensions: safety, efficacy, cost-effectiveness, innovativeness, appropriateness, and accessibility. Employing a prospective observational design, it primarily investigates the association of edaravone and dexrazoxane with clinical outcomes in patients with mild-to-moderate stroke, with subgroup analyses performed according to Trial of Org 10172 in Acute Stroke Treatment （TOAST ）classification.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Jan 2026
Typical duration for all trials
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
November 20, 2025
CompletedFirst Posted
Study publicly available on registry
December 3, 2025
CompletedStudy Start
First participant enrolled
January 20, 2026
CompletedPrimary Completion
Last participant's last visit for primary outcome
December 31, 2028
ExpectedStudy Completion
Last participant's last visit for all outcomes
December 31, 2028
January 15, 2026
January 1, 2026
2.9 years
November 20, 2025
January 14, 2026
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Proportion of patients with Modified Rankin Scale（mRS ）scores of 0-1
90 days
Secondary Outcomes (2)
Proportion of patients with mRS scores of 0-2
30 days
Percentage reduction in National Institutes of Health Stroke Scale （NIHSS ）score compared to pre-treatment
90 days after medication
Eligibility Criteria
Patients with ischemic stroke
You may qualify if:
- : Age≥18
- : Acute ischemic stroke in the anterior circulation occurring within 48 hours
- : Baseline NIHSS score of 1-15 points (mild stroke: baseline NIHSS score of 1-5 points; moderate stroke: baseline NIHSS score of 6-15 points)
- : Pre-onset mRS score≤1
- : Use of Edaravone (injection or tablets)
- : Exclude intracranial hemorrhage
- : Sign the informed consent form
You may not qualify if:
- : A head CT or MRI scan indicates the presence of intracranial hemorrhagic disease
- : Patients with cerebral embolism or suspected cerebral embolism who also have severe atrioventricular block, atrial fibrillation, myocardial infarction, valvular heart disease, infective endocarditis, or a heart rate below 50 beats per minute
- : Abnormal liver function (ALT or AST transaminase levels exceeding the upper limit of normal), abnormal kidney function (creatinine levels exceeding the upper limit of normal), or individuals with other severe systemic diseases, etc
- : Allergy to the test drug
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Related Publications (1)
Fu Y, Wang A, Tang R, Li S, Tian X, Xia X, Ren J, Yang S, Chen R, Zhu S, Feng X, Yao J, Wei Y, Dong X, Ling Y, Yi F, Deng Q, Guo C, Sui Y, Han S, Wen G, Li C, Dong A, Sun X, Wang Z, Shi X, Liu B, Fan D. Sublingual Edaravone Dexborneol for the Treatment of Acute Ischemic Stroke: The TASTE-SL Randomized Clinical Trial. JAMA Neurol. 2024 Feb 19;81(4):319-26. doi: 10.1001/jamaneurol.2023.5716. Online ahead of print.
PMID: 38372981RESULT
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Xiaofang Niu
Heze Municipal Hospital
- PRINCIPAL INVESTIGATOR
Leqing Zhang
Yanggu County People's Hospital
- PRINCIPAL INVESTIGATOR
Lei Duan
Zibo Central Hospital
- PRINCIPAL INVESTIGATOR
Kai Ren
Haiyang People's Hospital
- PRINCIPAL INVESTIGATOR
Rongrong Zhang
Sishui County People's Hospital
- PRINCIPAL INVESTIGATOR
Ping Yang
Jinan Fourth People's Hospital
- PRINCIPAL INVESTIGATOR
Ning Liu
Shandong Hospital of Integrated Traditional Chinese and Western Medicine
- PRINCIPAL INVESTIGATOR
Pengcheng Du
Qilu Hospital of Shandong University, Dezhou Branch
- PRINCIPAL INVESTIGATOR
Hui Liu
Jinan Municipal People's Hospital
- PRINCIPAL INVESTIGATOR
Xi Rong
Weifang Yidu Central Hospital
- PRINCIPAL INVESTIGATOR
Deyin Zhai
Linyi Traditional Chinese Medicine Hospital
- PRINCIPAL INVESTIGATOR
Zhiqiang Zhang
Anqiu People's Hospital
- PRINCIPAL INVESTIGATOR
Jiyong Wu
Shandong Provincial Second People's Hospital
- PRINCIPAL INVESTIGATOR
Meixia Wang
Jining Medical University Affiliated Hospital
- PRINCIPAL INVESTIGATOR
Ping Wang
Liaocheng People's Hospital
- PRINCIPAL INVESTIGATOR
Jiyao Li
Liaocheng Municipal People's Hospital
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Target Duration
- 90 Days
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Chief Pharmacist
Study Record Dates
First Submitted
November 20, 2025
First Posted
December 3, 2025
Study Start
January 20, 2026
Primary Completion (Estimated)
December 31, 2028
Study Completion (Estimated)
December 31, 2028
Last Updated
January 15, 2026
Record last verified: 2026-01